Following on from a deal announced last week, Swiss cancer company Oncoteq has unveiled an in-licensing agreement for an antibody-drug conjugate (ADC), codenamed TEQ102.
The company is expanding its development pipeline with what it believes could be a best-in-class ADC, obtaining rights from German firm Tubulis.
The candidate is being developed for people with CD30-positive lymphomas, including T-cell and Hodgkin’s lymphomas.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze